1. Li, X., et al., Human Coronaviruses: General Features. Reference Module in Biomedical Sciences, 2019.
2. Modrow, S., et al., Viruses: Definition, Structure, Classification. Molecular Virology, 2020: p. 17.
3. Peng, X., et al., Transmission routes of 2019-nCoV and controls in dental practice. International Journal of Oral Science, 2020. 12(1): p. 1-6.
4. Tellier, R., et al., Recognition of aerosol transmission of infectious agents: a commentary. BMC infectious diseases, 2019. 19(1): p. 101.
5. Chu, H., et al., Comparative replication and immune activation profiles of SARS-CoV-2 and SARS-CoV in human lungs: an ex vivo study with implications for the pathogenesis of COVID-19. Clinical Infectious Diseases, 2020.
6. Wang, S., et al., Coronaviruses and the Associated Potential Therapeutics for the Viral Infections. Journal of Infectious Diseases and Therapy, 2020. 8(2).
7. Lai, C.-C., et al., Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and corona virus disease-2019 (COVID-19): the epidemic and the challenges. International journal of antimicrobial agents, 2020: p. 105924.
8. Chan-Yeung, M. and R. Xu, SARS: epidemiology. Respirology 8 Suppl S9–14. 2003.
9. Hanege, F.M., et al., SARS‐CoV‐2 Presence in the Saliva, Tears, and Cerumen of COVID‐19 Patients. The Laryngoscope, 2021. 131(5): p. E1677-E1682.
10. Patel, K.P., et al., Transmission of SARS-CoV-2: an update of current literature. European Journal of Clinical Microbiology & Infectious Diseases, 2020: p. 1-7.
11. Kwon, T., N.N. Gaudreault, and J.A. Richt, Seasonal stability of SARS-CoV-2 in biological fluids. Pathogens, 2021. 10(5): p. 540.
12. Karia, R., et al., COVID-19 and its Modes of Transmission. SN comprehensive clinical medicine, 2020: p. 1-4.
13. Furuya, H., Prediction of Potential Respiratory Tract Infection from SARS-CoV-2 Through Hand-to-face Contact Transmission. Tokai J Exp Clin Med, 2020. 45(4): p. 170-175.
14. Masotti, F., et al., Transmission routes, preventive measures and control strategies of SARS-CoV-2 in the food factory. Critical Reviews in Food Science and Nutrition, 2021: p. 1-12.
15. Brazell, L.R., et al., Environmental Screening for Surface SARS-CoV-2 Contamination in Urban High-Touch Areas. medRxiv, 2021.
16. Kraay, A.N., et al., Risk for Fomite-Mediated Transmission of SARS-CoV-2 in Child Daycares, Schools, Nursing Homes, and Offices. Emerging infectious diseases, 2021. 27(4): p. 1229.
17. Zhou, P., et al., ZHANG w. Si Hr, zHu y, li B, HuanG cl, cHen HD, cHen J, luo y, Guo H, JianG rD, liu MQ, cHen y, SHen Xr, WanG X, zHenG XS, zHao K, cHen QJ, DenG F, liu ll, yan B, zHan FX, WanG yy, Xiao GF, SHi zl. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature, 2020. 579: p. 270-273.
18. Li, Y., et al., A Comprehensive Review of the Global Efforts on COVID-19 Vaccine Development. ACS Central Science, 2021. 7(4): p. 512-533.
19. Li, Q. and H. Lu, Latest updates on COVID-19 vaccines. BioScience Trends, 2020.
20. Carvalho, J.C., et al., Hypersensitivity Reactions to Vaccines: Current Evidence and Standards for SARS-CoV-2 Vaccines. Acta Médica Portuguesa, 2021. 34(13).
21. Burgess, L.H., et al., COVID-19: The Vaccine Race Continues. HCA Healthcare Journal of Medicine, 2021. 2(2): p. 2.
22. Savarino, A., et al., Effects of chloroquine on viral infections: an old drug against today's diseases. The Lancet infectious diseases, 2003. 3(11): p. 722-727.
23. Dan, Z., D. Sheng-Ming, and T. Qiang, COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression| Journal of Antimicrobial Chemotherapy. J Antimicrob Chemother, 2020: p. 1-4.
24. Colson, P., J.-M. Rolain, and D. Raoult, Chloroquine for the 2019 novel coronavirus SARS-CoV-2. International journal of antimicrobial agents, 2020. 55(3): p. 105923.
25. Barlow, A., et al., Review of emerging pharmacotherapy for the treatment of coronavirus disease 2019. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2020. 40(5): p. 416-437.
26. Dong, L., S. Hu, and J. Gao, Discovering drugs to treat coronavirus disease 2019 (COVID-19). Drug discoveries & therapeutics, 2020. 14(1): p. 58-60.
27. Wang, M., et al., Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell research, 2020. 30(3): p. 269-271.
28. Awadasseid, A., et al., Effective drugs used to combat SARS-CoV-2 infection and the current status of vaccines. Biomedicine & Pharmacotherapy, 2021: p. 111330.
29. Lamb, Y.N., Remdesivir: first approval. Drugs, 2020: p. 1-9.
30. Malin, J.J., et al., Remdesivir against COVID-19 and other viral diseases. Clinical microbiology reviews, 2021. 34(1).
31. Aleissa, M.M., et al., New perspectives on antimicrobial agents: remdesivir treatment for COVID-19. Antimicrobial agents and chemotherapy, 2021. 65(1).
32. Choy, K.-T., et al., Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro. Antiviral research, 2020. 178: p. 104786.
33. Tu, Y.-F., et al., A review of SARS-CoV-2 and the ongoing clinical trials. International journal of molecular sciences, 2020. 21(7): p. 2657.
34. Chakraborty, S., et al., SARS-CoV-2 vaccines in advanced clinical trials: Where do we stand. Advanced Drug Delivery Reviews, 2021.
35. Pandey, A., et al., Potential therapeutic targets for combating SARS-CoV-2: Drug repurposing, clinical trials and recent advancements. Life sciences, 2020: p. 117883.
36. Molavi, Z., et al., Identification of FDA approved drugs against SARS-CoV-2 RNA dependent RNA polymerase (RdRp) and 3-chymotrypsin-like protease (3CLpro), drug repurposing approach. Biomedicine & Pharmacotherapy, 2021: p. 111544.
37. Gul, S., et al., In silico identification of widely used and well-tolerated drugs as potential SARS-CoV-2 3C-like protease and viral RNA-dependent RNA polymerase inhibitors for direct use in clinical trials. Journal of Biomolecular Structure and Dynamics, 2020: p. 1-20.
38. Udofia, I.A., et al., In silico studies of selected multi-drug targeting against 3CLpro and nsp12 RNA-dependent RNA-polymerase proteins of SARS-CoV-2 and SARS-CoV. Network Modeling Analysis in Health Informatics and Bioinformatics, 2021. 10(1): p. 1-12.
39. Basu, A., A. Sarkar, and U. Maulik, Computational approach for the design of potential spike protein binding natural compounds in SARS-CoV2. 2020.
40. Oyewole, O.O.O., USE HERBS TO COMBAT COVID-19 INFECTION.
41. Elendran, S., et al., The physicochemical properties of geraniin, a potential antihyperglycemic agent. Pharmaceutical biology, 2015. 53(12): p. 1719-1726.
42. Huang, F., et al., A review of therapeutic agents and Chinese herbal medicines against SARS-COV-2 (COVID-19). Pharmacological Research, 2020: p. 104929.
43. Osuntokun, O.T., Synergistic efficacy of Aframomum melegueta [Roscoe] K. Schum and Spondias mombin (Linn), A predictive treatment of SARS-CoV-2 (COVID-19) Infection.
44. Khaerunnisa, S., et al., Potential inhibitor of COVID-19 main protease (Mpro) from several medicinal plant compounds by molecular docking study. Prepr. doi10, 2020. 20944: p. 1-14.
45. Falang, K.D., et al., Combinatorial Evaluation of Antiviral Activity of some Nigerian Medicinal Plants on SARS-CoV-2Combinatorial Evaluation of Antiviral Activity of some Nigerian Medicinal Plants on SARS-CoV-2. Journal of Complementary and Alternative Medical Research, 2020: p. 38-50.
46. Salman, S., et al., Virtual screening of immunomodulatory medicinal compounds as promising anti-SARS-COV-2 inhibitors. Future Virology, 2020(0).
47. Duvall, C.S., On the origin of the tree Spondias mombin in Africa. Journal of Historical Geography, 2006. 32(2): p. 249-266.
48. Silva, A., et al., Antiviral activities of extracts and phenolic components of two Spondias species against dengue virus. Journal of Venomous Animals and Toxins Including Tropical Diseases, 2011. 17(4): p. 406-413.
49. Corthout, J., et al., Antiviral caffeoyl esters from Spondias mombin. Phytochemistry, 1992. 31(6): p. 1979-1981.
50. Corthout, J., et al., Antiviral ellagitannins from Spondias mombin. Phytochemistry, 1991. 30(4): p. 1129-1130.
51. de Pinto, G.L., et al., Structural investigation of the polysaccharide of Spondias mombin gum. Carbohydrate polymers, 2000. 43(2): p. 105-112.
52. Nworu, C.S., et al., The leaf extract of Spondias mombin L. displays an anti-inflammatory effect and suppresses inducible formation of tumor necrosis factor-α and nitric oxide (NO). Journal of immunotoxicology, 2011. 8(1): p. 10-16.
53. Sasidharan, S., et al., Extraction, isolation and characterization of bioactive compounds from plants’ extracts. African Journal of Traditional, Complementary and Alternative Medicines, 2011. 8(1).
54. Akram, M., et al., Antiviral potential of medicinal plants against HIV, HSV, influenza, hepatitis, and coxsackievirus: A systematic review. Phytotherapy Research, 2018. 32(5): p. 811-822.
55. Ben-Shabat, S., et al., Antiviral effect of phytochemicals from medicinal plants: applications and drug delivery strategies. Drug Delivery and Translational Research, 2020: p. 1-14.
56. Adams, M., F. Gmünder, and M. Hamburger, Plants traditionally used in age related brain disorders—a survey of ethnobotanical literature. Journal of Ethnopharmacology, 2007. 113(3): p. 363-381.
57. Adedokun, M., et al., Socio–economic importance and utilization of Spondias mombin in Nigeria. Asian Pacific Journal of Tropical Medicine, 2010. 3(3): p. 232-234.
58. Hermans, M., A. Akoègninou, and J. van der Maesen, Medicinal plants used to treat malaria in southern Benin. Economic Botany, 2004. 58(1): p. S239-S252.
59. Idowu, O., et al., Ethnobotanical survey of antimalarial plants used in Ogun State, Southwest Nigeria. African Journal of Pharmacy and Pharmacology, 2010. 4(2): p. 055-060.
60. Iyamah, P. and M. Idu, Ethnomedicinal survey of plants used in the treatment of malaria in Southern Nigeria. Journal of ethnopharmacology, 2015. 173: p. 287-302.
61. Traore, M., et al., Ethnobotanical survey on medicinal plants used by Guinean traditional healers in the treatment of malaria. Journal of ethnopharmacology, 2013. 150(3): p. 1145-1153.
62. Fred-Jaiyesimi, A., A. Kio, and W. Richard, α-Amylase inhibitory effect of 3β-olean-12-en-3-yl (9Z)-hexadec-9-enoate isolated from Spondias mombin leaf. Food Chemistry, 2009. 116(1): p. 285-288.
63. Gbolade, A. and A. Adeyemi, Anthelmintic activities of three medicinal plants from Nigeria. Fitoterapia, 2008. 79(3): p. 223-225.
64. Ogbole, O. and E. Ajaiyeoba, Traditional management of tuberculosis in Ogun State of Nigeria: the practice and ethnobotanical survey. African Journal of Traditional, Complementary and Alternative Medicines, 2010. 7(1).
65. Erhabor, J., M. Idu, and F. Udo, Ethnomedicinal survey of medicinal plants used in the treatment of male infertilty among the IFA Nkari People of Ini Local Government area of Akwa Ibom State, Nigeria. Research Journal of Recent Sciences ______________________________________________________________ ISSN, 2013. 2277: p. 2502.
66. Awogbindin, I., et al., Assessment of flavonoid content, free radical scavenging and hepatoprotective activities of Ocimum gratissimum and Spondias mombin in rats treated with dimethylnitrosamine. Arch Bas Appl Med, 2014. 2(1): p. 45-54.
67. Ishola, I.O., B.O. Ikuomola, and O.O. Adeyemi, Protective role of Spondias mombin leaf and Cola acuminata seed extracts against scopolamineinduced cognitive dysfunction. Alexandria Journal of Medicine, 2018. 54(1): p. 27-39.
68. Sabiu, S., et al., Indomethacin-induced gastric ulceration in rats: protective roles of Spondias mombin and Ficus exasperata. Toxicology reports, 2015. 2: p. 261-267.
69. Abad, M., et al., Antiinflammatory activity of some medicinal plant extracts from Venezuela. Journal of Ethnopharmacology, 1996. 55(1): p. 63-68.
70. Oladunmoye, M., Comparative evaluation of the effects of leaf extract from Spondias mombin on rats with induced infections from Bacillus cereus and Clostridium sporogenes. Research Journal of Phytochemistry, 2010. 4(4): p. 264-269.
71. Igwe, C., et al., Evaluation of the chemical compositions of the leaf of Spondias mombin Linn from Nigeria. Australian Journal of Basic and Applied Sciences, 2010. 4(5): p. 706-710.
72. Maduka, H., et al., Phytochemical, antioxidant and microbial inhibitory effects of Spondias mombin leaf and stem bark extracts. J Pharm Biol Sci, 2014. 9(2): p. 14-17.
73. Njoku, P. and M. Akumefula, Phytochemical and nutrient evaluation of Spondias mombin leaves. Pak. J. Nutr, 2007. 6(6): p. 613-615.
74. Cheng, H.S., S.H. Ton, and K.A. Kadir, Ellagitannin geraniin: a review of the natural sources, biosynthesis, pharmacokinetics and biological effects. Phytochemistry reviews, 2017. 16(1): p. 159-193.
75. Perera, A., S.H. Ton, and U.D. Palanisamy, Perspectives on geraniin, a multifunctional natural bioactive compound. Trends in Food Science & Technology, 2015. 44(2): p. 243-257.
76. Choi, J.-G., et al., Antiviral activity of ethanol extract of Geranii Herba and its components against influenza viruses via neuraminidase inhibition. Scientific reports, 2019. 9(1): p. 1-12.
77. Liu, C., et al., Identification of hydrolyzable tannins (punicalagin, punicalin and geraniin) as novel inhibitors of hepatitis B virus covalently closed circular DNA. Antiviral research, 2016. 134: p. 97-107.
78. Yang, C.-M., et al., The in vitro activity of geraniin and 1, 3, 4, 6-tetra-O-galloyl-β-d-glucose isolated from Phyllanthus urinaria against herpes simplex virus type 1 and type 2 infection. Journal of ethnopharmacology, 2007. 110(3): p. 555-558.
79. Yang, Y., et al., Antiviral effect of geraniin on human enterovirus 71 in vitro and in vivo. Bioorganic & medicinal chemistry letters, 2012. 22(6): p. 2209-2211.
80. Li, J., et al., Anti-hepatitis B virus activities of Geranium carolinianum L. extracts and identification of the active components. Biological and Pharmaceutical Bulletin, 2008. 31(4): p. 743-747.
81. Siqueira, E.M.d.S., et al., Antiviral Potential of Spondias mombin L. Leaves Extract Against Herpes Simplex Virus Type-1 Replication Using In Vitro and In Silico Approaches. Planta Medica, 2020. 86(07): p. 505-515.
82. Ahmad, S.A.A., et al., Efficacy of geraniin on dengue virus type-2 infected BALB/c mice. Virology journal, 2019. 16(1): p. 26.
83. Haddad, J.G., et al., The Geraniin-Rich Extract from Reunion Island Endemic Medicinal Plant Phyllanthus phillyreifolius Inhibits Zika and Dengue Virus Infection at Non-Toxic Effect Doses in Zebrafish. Molecules, 2020. 25(10): p. 2316.
84. Ahmad, S.A.A., et al., Geraniin extracted from the rind of Nephelium lappaceum binds to dengue virus type-2 envelope protein and inhibits early stage of virus replication. Virology journal, 2017. 14(1): p. 1-13.
85. Mahmood, N., et al., Constituents of Cuscuto reflexa are anti-HIV Agents. Antiviral chemistry and chemotherapy, 1997. 8(1): p. 70-74.
86. Leaf-nosed bat, in Encyclopædia Britannica. 2009, Encyclopædia Britannica Online.
87. Wu, C., et al., Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods. Acta Pharmaceutica Sinica B, 2020.
88. Kirchdoerfer, R.N. and A.B. Ward, Structure of the SARS-CoV nsp12 polymerase bound to nsp7 and nsp8 co-factors. Nature communications, 2019. 10(1): p. 1-9.
89. Subissi, L., et al., SARS-CoV ORF1b-encoded nonstructural proteins 12–16: replicative enzymes as antiviral targets. Antiviral research, 2014. 101: p. 122-130.
90. Imbert, I., et al., A second, non‐canonical RNA‐dependent RNA polymerase in SARS Coronavirus. The EMBO journal, 2006. 25(20): p. 4933-4942.
91. Chu, C.K., et al., Antiviral activity of nucleoside analogues against SARS-coronavirus (SARS-CoV). Antiviral Chemistry and Chemotherapy, 2006. 17(5): p. 285-289.
92. Wan, Y., et al., Receptor recognition by the novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS coronavirus. Journal of virology, 2020. 94(7).
93. Anand, K., et al., Coronavirus main proteinase (3CLpro) structure: basis for design of anti-SARS drugs. Science, 2003. 300(5626): p. 1763-1767.
94. Mesecar, A., A taxonomically-driven approach to development of potent, broad-spectrum inhibitors of coronavirus main protease including SARS-CoV-2 (COVID-19). Be Publ, 2020.
95. Yang, H., et al., The crystal structures of severe acute respiratory syndrome virus main protease and its complex with an inhibitor. Proceedings of the National Academy of Sciences, 2003. 100(23): p. 13190-13195.
96. Bacha, U., et al., Identification of novel inhibitors of the SARS coronavirus main protease 3CLpro. Biochemistry, 2004. 43(17): p. 4906-4912.
97. Berman, H.M., et al., The protein data bank. Acta Crystallographica Section D: Biological Crystallography, 2002. 58(6): p. 899-907.
98. Gao, Y., et al., Structure of the RNA-dependent RNA polymerase from COVID-19 virus. Science, 2020. 368(6492): p. 779-782.
99. Liu, X., et al., The crytal structure of 2019-nCoV main protease in complex with an inhibitor N3. RCSB Protein Data Bank, 2020.
100. Yan, R., et al., Structural basis for the recognition of the 2019-nCoV by human ACE2. BioRxiv, 2020.
101. Pettersen, E.F., et al., UCSF Chimera—a visualization system for exploratory research and analysis. Journal of computational chemistry, 2004. 25(13): p. 1605-1612.
102. ChemAxon, L., Marvinsketch. 2013, ChemAxon Cambridge.
103. Hanwell, M.D., et al., Avogadro: an advanced semantic chemical editor, visualization, and analysis platform. Journal of cheminformatics, 2012. 4(1): p. 17.
104. Trott, O. and A.J. Olson, AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. Journal of computational chemistry, 2010. 31(2): p. 455-461.
105. Daina, A., O. Michielin, and V. Zoete, SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Scientific reports, 2017. 7: p. 42717.
106. Lipinski, C.A., Lipinski's rule of five.
107. Ganesan, A., The impact of natural products upon modern drug discovery. Current opinion in chemical biology, 2008. 12(3): p. 306-317.
108. Ali, A.F.A.I., Is there a Lipinski-analogous set of rules for natural products? 2012.
109. Case, D., et al., Amber 2018: San Francisco. 2018, California.
110. Le Grand, S., A.W. Götz, and R.C. Walker, SPFP: Speed without compromise—A mixed precision model for GPU accelerated molecular dynamics simulations. Computer Physics Communications, 2013. 184(2): p. 374-380.
111. Salomon-Ferrer, R., et al., Routine microsecond molecular dynamics simulations with AMBER on GPUs. 2. Explicit solvent particle mesh Ewald. Journal of chemical theory and computation, 2013. 9(9): p. 3878-3888.
112. Maier, J.A., et al., ff14SB: improving the accuracy of protein side chain and backbone parameters from ff99SB. Journal of chemical theory and computation, 2015. 11(8): p. 3696-3713.
113. Case, D.A., et al., The Amber biomolecular simulation programs. Journal of computational chemistry, 2005. 26(16): p. 1668-1688.
114. Berendsen, H.J., et al., Molecular dynamics with coupling to an external bath. The Journal of chemical physics, 1984. 81(8): p. 3684-3690.
115. Kräutler, V., W.F. Van Gunsteren, and P.H. Hünenberger, A fast SHAKE algorithm to solve distance constraint equations for small molecules in molecular dynamics simulations. Journal of computational chemistry, 2001. 22(5): p. 501-508.
116. Roe, D.R. and T.E. Cheatham III, PTRAJ and CPPTRAJ: software for processing and analysis of molecular dynamics trajectory data. Journal of chemical theory and computation, 2013. 9(7): p. 3084-3095.
117. Seifert, E., OriginPro 9.1: Scientific Data Analysis and Graphing Software Software Review. 2014, ACS Publications.
118. Wang, C., et al., Recent developments and applications of the MMPBSA method. Frontiers in molecular biosciences, 2018. 4: p. 87.
119. Miller III, B.R., et al., MMPBSA. py: an efficient program for end-state free energy calculations. Journal of chemical theory and computation, 2012. 8(9): p. 3314-3321.
120. Du, X., et al., Insights into protein–ligand interactions: mechanisms, models, and methods. International journal of molecular sciences, 2016. 17(2): p. 144.
121. Jejurikar, B.L. and S.H. Rohane, Drug Designing in Discovery Studio. Asian Journal of Research in Chemistry, 2021. 14(2): p. 135-138.
122. Hall Jr, D.C. and H.-F. Ji, A search for medications to treat COVID-19 via in silico molecular docking models of the SARS-CoV-2 spike glycoprotein and 3CL protease. Travel medicine and infectious disease, 2020: p. 101646.
123. ul Qamar, M.T., et al., Structural basis of SARS-CoV-2 3CLpro and anti-COVID-19 drug discovery from medicinal plants. Journal of pharmaceutical analysis, 2020.
124. Wang, M., R. Cao, and L. Zhang, Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019 nCoV) in vitro [published online February 4, 2020]. Cell Res. doi. 10.
125. Muhseen, Z.T., et al., Promising terpenes as SARS-CoV-2 spike receptor-binding domain (RBD) attachment inhibitors to the human ACE2 receptor: integrated computational approach. Journal of molecular liquids, 2020. 320: p. 114493.
126. Raha, K. and K.M. Merz Jr, Calculating binding free energy in protein–ligand interaction. Annual reports in computational chemistry, 2005. 1: p. 113-130.
127. Wlodawer, A., Rational approach to AIDS drug design through structural biology. Annual review of medicine, 2002. 53(1): p. 595-614.
128. Salmaso, V. and S. Moro, Bridging molecular docking to molecular dynamics in exploring ligand-protein recognition process: An overview. Frontiers in pharmacology, 2018. 9: p. 923.
129. Durrant, J.D. and J.A. McCammon, Molecular dynamics simulations and drug discovery. BMC biology, 2011. 9(1): p. 1-9.
130. Karshikoff, A., L. Nilsson, and R. Ladenstein, Rigidity versus flexibility: the dilemma of understanding protein thermal stability. The FEBS journal, 2015. 282(20): p. 3899-3917.
131. Pitera, J.W., Expected distributions of root-mean-square positional deviations in proteins. The Journal of Physical Chemistry B, 2014. 118(24): p. 6526-6530.
132. Bornot, A., C. Etchebest, and A.G. De Brevern, Predicting protein flexibility through the prediction of local structures. Proteins: Structure, Function, and Bioinformatics, 2011. 79(3): p. 839-852.
133. Suárez, D. and N. Díaz, SARS-CoV-2 Main Protease: A Molecular Dynamic Study. 2020.
134. Pace, C.N., et al., Forces contributing to the conformational stability of proteins. The FASEB journal, 1996. 10(1): p. 75-83.
135. Koulgi, S., et al., Remdesivir-bound and ligand-free simulations reveal the probable mechanism of inhibiting the RNA dependent RNA polymerase of severe acute respiratory syndrome coronavirus 2. RSC Advances, 2020. 10(45): p. 26792-26803.
136. Gur, M., et al., Exploring Conformational Transition of 2019 Novel Coronavirus Spike Glycoprotein Between Its Closed and Open States Using Molecular Dynamics Simulations. bioRxiv, 2020.
137. Geerts, T. and Y. Vander Heyden, In silico predictions of ADME-Tox properties: drug absorption. Combinatorial chemistry & high throughput screening, 2011. 14(5): p. 339-361.
138. Kalita, J.M., et al., ADVANCES IN COMPUTER AIDED DRUG DESIGN. Universal J of Pharm Sci Res, 2015. 1: p. 17-22.
139. Daina, A., O. Michielin, and V. Zoete, SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Scientific reports, 2017. 7(1): p. 1-13.
140. Péronnet, F., et al., Pharmacokinetic analysis of absorption, distribution and disappearance of ingested water labeled with D 2 O in humans. European journal of applied physiology, 2012. 112(6): p. 2213-2222.
141. Daina, A. and V. Zoete, A boiled‐egg to predict gastrointestinal absorption and brain penetration of small molecules. ChemMedChem, 2016. 11(11): p. 1117.
142. Lipinski, C.A., et al., Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Advanced drug delivery reviews, 1997. 23(1-3): p. 3-25.
143. Struck, S., et al., Toxicity versus potency: elucidation of toxicity properties discriminating between toxins, drugs, and natural compounds, in Genome Informatics 2008: Genome Informatics Series Vol. 20. 2008, World Scientific. p. 231-242.
144. Olotu, F.A., G. Munsamy, and M.E. Soliman, Does Size Really Matter? Probing the Efficacy of Structural Reduction in the Optimization of Bioderived Compounds–A Computational “Proof-of-Concept”. Computational and Structural Biotechnology Journal, 2018. 16: p. 573-586.